Lipoblastoma is a benign uncommon soft-tissue-tumor resembling fetal adipose tissue affecting mainly children under three years of age. In lipoblastoma, the typical cytogenetic changes are clonal rearrangements involving chromosomal region 8q11→q13. The oncogene PLAG1 (pleomorphic adenoma gene 1) is located within this chromosomal region on band 8q12. Recent reports have demonstrated that in lipoblastoma, the PLAG1 gene is activated by ‘promoter-swapping’. Herein, we demonstrate that in lipoblastoma, the PLAG1 gene may also be activated by low-level amplification. We report on a lipoblastoma with the karyotype 48∼50,XX,del(8)(q13q21.2),+del(8)(q13q21.2)×4[cp12]. Subsequent FISH analysis on uncultured tumor cells confirmed this result and demonstrated a low-level amplification of the chromosomal region 8pter→8q13 and 8q21.2→8qter. A partial monosomy was seen for the chromosomal region 8q13→8q21.2. No other gains or losses were observed by CGH analysis. RT-PCR analysis showed that the PLAG1 gene is activated in the tumor sample of the lipoblastoma analyzed, in contrast to normal fatty tissue without PLAG1 expression. In conclusion, our results demonstrate that low-level amplification is a further mechanism of PLAG1 activation in lipoblastomas.

1.
Åström AK, Voz ML, Kas K, Röijer E, Wedell B, et al: Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res 59:918–923 (1999).
2.
Åström AK, D’Amore ESG, Sainati L, Panarello C, Morerio C, et al: Evidence of involvement of the PLAG1 gene in lipoblastomas. Int J Oncol 16:1107–1110 (2000).
3.
Barch MJ, Knutsen T, Spurbeck JL: The AGT Cytogenetics Laboratory Manual (Lippincott-Raven, Philadelphia 1997).
4.
Batanian JR, Brink DS, Thorpe CM, Haddad BR: Case of lipoblastoma with two derivative chromosomes 8 containing homogeneously staining-like regions and a review of the literature: lipoblastoma and chromosome 8. Cancer Genet Cytogenet 125:10–13 (2001).
5.
Bourelle S, Viehweger E, Launay F, Quilichini B, Bouvier C, et al: Lipoblastoma and lipoblastomatosis. J Pediatr Orthop B 15:356–361 (2006).
6.
Brandal P, Bjerkehagen B, Heim S: Rearrangement of chromosomal region 8q11–13 in lipomatous tumors: correlation with lipoblastoma morphology. J Pathol 208:388–394 (2006).
7.
Craver RD, Henrich S, Kao YS: Fibrous lipoblastoma with 8q11.2 abnormality. Cancer Genet Cytogenet 171:112–114 (2006).
8.
Dei Tos AP, Dal Cin P: The role of cytogenetics in the classification of soft tissue tumors. Virchows Arch 431:83–94 (1997).
9.
Du Manoir S, Schrock E, Bentz M, Speicher MR, Joos S, et al: Quantitative analysis of comparative genomic hybridization. Cytometry 19:27–41 (1995).
10.
Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone (IARC Press, Lyon 2002).
11.
Fletcher JA, Kozakewich HP, Schoenberg ML, Morton CC: Cytogenetic findings in pediatric adipose tumors: consistent rearrangement of chromosome 8 in lipoblastoma. Genes Chromo- somes Cancer 6:24–29 (1993).
12.
Gisselsson D, Hibbard MK, Dal Cin P, Sciot R, Hsi BL, et al: PLAG1 alterations in lipoblastoma: involvement in varied mesenchymal cell types and evidence for alternative oncogenic mechanisms. Am J Pathol 159:955–962 (2001).
13.
Hibbard MK, Kozakewich HP, Dal cin P, Sciot R, Tan X, et al: PLAG1 fusion oncogenes in lipoblastoma. Cancer Res 60:4869–4872 (2000).
14.
ISCN 1995: An International System for Human Cytogenetic Nomenclature, Mitelman F (ed) (S. Karger, Basel 1995).
15.
Kas K, Voz ML, Röijer E, Åström AK, Meyen E, et al: Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 15:170–174 (1997a).
16.
Kas K, Röijer E, Voz M, Meyen E, Stenman G, et al: A 2-Mb YAC contig and physical map covering the chromosome 8q12 breakpoint cluster region in pleomorphic adenomas of the salivary glands. Genomics 43:349–358 (1997b).
17.
Mentzel T, Calonje E, Fletcher CD: Lipoblastoma and lipoblastomatosis: a clinicopathological study of 14 cases. Histopathology 23:527–533 (1993).
18.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215 (1988).
19.
Morerio C, Rapella A, Rosanda C, Tassano E, Gambini C, et al: PLAG1-HAS2 fusion in lipoblastoma with masked 8q intrachromosomal rearrangement. Cancer Genet Cytogenet 156:183–184 (2005).
20.
Röpke A, Erbersdobler A, Hammerer P, Palisaar J, John K, et al: Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy. Prostate 59:59–68 (2004).
21.
Sandberg AA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipoma. Cancer Genet Cytogenet 150:93–115 (2004).
22.
Sandberg AA, Gibas Z, Saren E, Li FP, Limon J, Tebbi CK: Chromosome abnormalities in two benign adipose tumors. Cancer Genet Cytogenet 22:55–61 (1986).
23.
Sciot R, Mandahl N: Lipoblastoma/Lipoblastomatosis; in Fletcher CDM, Unni KK, Mertens F (eds): World Health Organization: Classification of Tumours. Pathology and Genetics of Tumors of Soft Tissue and Bone, pp 26–27 (IARC Press, Lyon 2002).
24.
Sciot R, De Wever I, Debiec-Rychter M: Lipoblastoma in a 23-year-old male: distinction from atypical lipomatous tumor using cytogenetic and fluorescence in-situ hybridization analysis. Virchows Arch 442:468–471 (2003).
25.
Somers GR, Teshima I, Nasr A, Cook A, Khoury AE, Taylor GP: Intrascrotal lipoblastoma with a complex karyotype: a case report and review of the literature. Arch Pathol Lab Med 128:797–800 (2004).
26.
Voz ML, Åström AK, Kas K, Mark J, Stenman G, Van de Ven WJ: The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene 16:1409–1416 (1998).
27.
Voz ML, Agten NS, Van de Ven WJ, Kas K: PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res 60:106–113 (2000).
28.
Weber RG, Pietsch T, von Schweinitz D, Lichter P: Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 157:571–578 (2000).
29.
Wieland I, Arden KC, Michels D, Klein-Hitpass L, Bohm M, et al: Isolation of DICE1: a gene frequently affected by LOH and downregulated in lung carcinomas. Oncogene 18:4530–4537 (1999).
30.
Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, et al: Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 39:126–137 (2004).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.